Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

Opening
Remarks

Paul Villanti, Executive Director Programs, Movember Christoper Sweeney, ICECaP Principal Investigator, Medical Oncology, Dana-Farber Cancer Institute

Agenda

ICECaP Adjuvant Presentations

ICECaP Updates

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

Update on data collection for ICECaP2

Praful Ravi

Medical Oncology,
Dana-Farber Cancer Institute.

View Presentation

Example of assessing new PSA based endpoints

Wanling Xie

Biostatistics,
Dana-Farber Cancer Institute.

Health Economics Presentations

Progress on creating a health economics model in adjuvant prostate cancer setting

Richard De Abreu Lourenco

Health Economics,
University of Technology Sydney

Discuss goal to credential QALY gained from preventing a PSA relapse as an endpoint

Chris Sweeney

ICECaP Principal Investigator,
Medical Oncology,
Dana-Farber Cancer Institute.

Harmonization Presentations

Progress of writing a guidance document for conduct of adjuvant trials 

Anis Hamid
Medical Oncology, University of Melbourne

STOPCAP Presentations

Progress on IPD data collection and network meta-analyses for treatment effects

Jayne Tierney

Evidence Synthesis
University College London

Progress on prognostic models and surrogacy

Susan Halabi

Biostatistics and Bioinformatics, Duke University

Proposal of simple prognostic model

Chris Sweeney

Medical Oncology
Dana-Farber Cancer Institute

ICECaP Biology Presentations

Progress: prelim data, sample collection, and plans: 

  • M1HSPC: STAMPEDE-ADT, doc, abi; CHAARTED; ENZAMET, PEACE-1
  • Adjuvant: STAMPEDE-ADT, doc, abi; NRG; ENZARAD

Gerhardt Attard
Medical Oncology, University College London